ARTAN Bio
Michael Torres and Anthony Schwartz. Suppressor tRNAs for nonsense mutations.
Case Studies
Impact in Action
Real Bio ecosystem projects: the problem, the raise, and what shipped.
PeptAI
An agent fleet that designs peptides, validates them computationally, and books its own wet-lab work. First launch on the coin-to-company framework.
HairDAO
A patient community funding hair loss research since 2021.
LAUNCHED ON BIO
Selected projects from idea to protocol
Selected projects from idea to protocol
Peptai
PeptAI is an autonomous AI agent that discovers new peptide drug candidates. It designs peptides computationally, then pushes them through an 8-gate validation pipeline. Every result is published on-chain (blockchain) so anyone can verify the science. Once a candidate passes validation, it's sent to the wet-lab for synthesis and binding assays. PeptAI is receptor agnostic, however first programmes target GLP1R, KISS1R, OX2R and several other GPCRs.
SpineDAO
Revolutionizing spine care for millions worldwide. By leveraging blockchain, AI, and collaborative decentralized science, SpineDAO creates an open platform for optimizing surgical decisions, improving patient outcomes, and democratizing access to spine knowledge.
Cerebrum DAO
Cerebrum DAO is building the world’s largest engaged community focused on enabling scientific breakthroughs that prevent the onset of neurodegeneration and extend our healthy brain years.
VitaStem by Aubrai
VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline…
Neuron-Gale
The galectin-3 Inhibitors project tests a small molecule under development for peripheral indications for treating neuroinflammation in an Alzheimer’s mouse model. By blocking galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. Galectin-3 is involved in neuroinflammation, thereby the inhibitor has a potential to be used in multiple neurodegenerative diseases.
eDMT Commons
eDMT Commons enables shared governance over multiple R&D efforts into how the brain regulates its own DMT. This Commons IPT coordinates funding across diverse approaches, accelerating discovery while ensuring knowledge remains community-governed. Token holders benefit from any project funded by or joining the consortium. The flagship project seeks to uncover how endogenous DMT is regulated in the mammalian brain by isolating and sequencing enzymes that act as an “off switch” for DMT…